Business Context and Reporting Period
This Form 8-K filing by Aquestive Therapeutics, Inc. (AQST) reports on events occurring on April 22, 2024, regarding the completion of an underwritten public offering of common stock previously announced on March 19, 2024.
Key Financial Metrics
- Total Gross Proceeds: Approximately $77.5 million (before deducting underwriting commissions and offering expenses).
- Shares Issued: 16,666,667 shares initially, plus 559,801 shares from the over-allotment exercise.
- Offering Price: $4.50 per share.
- Underwriters: Leerink Partners and Piper Sandler (joint bookrunning managers); Oppenheimer & Co. (lead manager).
Material Changes
On April 22, 2024, the underwriters exercised their option to purchase 559,801 additional shares to cover over-allotments. This action finalized the total capital raised from the offering at approximately $77.5 million. The filing does not provide comparative financial data for prior periods as it is a current event report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the offering terms. The securities were offered pursuant to a Registration Statement on Form S-3 declared effective on April 5, 2021.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and commissions, as the $77.5 million figure is gross.
- Confirm the dilution impact of the total 17,226,468 shares issued on existing shareholders.
- Review the final prospectus supplement filed on March 21, 2024, for detailed use of proceeds.
- Check subsequent filings for the actual cash balance impact on the company's liquidity position.